HQ-Star 200 Tablet contains Hydroxychloroquine 200 mg, an antimalarial and immunomodulatory agent commonly used in the treatment of malaria, rheumatoid arthritis, and systemic lupus erythematosus. Hydroxychloroquine exerts its therapeutic effects by interfering with lysosomal activity and autophagy, modulating immune responses, and inhibiting parasite growth. This medication is indicated for the prevention and treatment of acute attacks of malaria caused by Plasmodium species, as well as for managing autoimmune conditions by reducing inflammation and immune system overactivity. HQ-Star 200 Tablet should be administered under medical supervision with dosage tailored according to the specific condition and patient response. Common adverse effects may include gastrointestinal disturbances such as nausea, vomiting, and abdominal pain, as well as headache and dizziness. Prolonged use requires monitoring for retinal toxicity through regular ophthalmologic examinations, as hydroxychloroquine can cause irreversible retinal damage in rare cases. Caution is advised in patients with pre-existing retinal or visual field changes, hepatic or renal impairment, and those with hypersensitivity to the drug. HQ-Star 200 Tablet is contraindicated in patients with known hypersensitivity to hydroxychloroquine or related compounds. Use during pregnancy and lactation should be evaluated by a healthcare professional to balance potential benefits and risks.